Labs are already lining up to try out a new duplex sequencing workflow from Illumina that the company hopes will bolster its presence in the blood-based circulating tumor DNA market, especially in minimal/molecular residual disease (MRD).
Illumina announced Nov. 9 an early access program for the duplex kit, which is research-use only. The workflow supports cfDNA input of 5 ng to 10 ng and delivers quality scores above Q65, Illumina said, or fewer than one error per million bases. Moreover, Illumina claimed the chemistry reproducibly detected ctDNA at levels of 2.5 parts per million with 10 ng of input.
“MRD research is moving fast, and new tools are making it possible to bring ultrasensitive, tumor-informed analysis in-house,” Matija Snuderl, director of molecular pathology at NYU Langone Health — already an early access user, said in a statement.
But whether the test labs will embrace the product remains to be seen. Mayo Clinic will be an early access site, according to Gang Zheng, a pathologist who described his lab’s implementation of Illumina’s Whole-Genome Sequencing Oncology Prep product for MRD research in a company-sponsored talk at the Association for Molecular Pathology meeting Nov. 11.
Afterwards, he told Ion Genomics that adding the duplex chemistry on top of that is not a guarantee. “The problem is the additional workflow,” he said.
Like other duplex chemistries, this product analyzes both strands of a DNA molecule to increase confidence in variant detection. According to Illumina’s website, the process begins with enzymatic treatment of cfDNA to “prepare fragment ends and reduce sources of downstream error,” then “complementary blocked adapters are ligated to each end of the DNA fragment, then unblocked to enable intramolecular priming.”
Keeping the strands together enables them to be sequenced within the same cluster on an Illumina sequencer and compared to generate a consensus read. Libraries are prepared in approximately 6 to 7 hours using
2x175 bp reads on the NovaSeq X Series.
Illumina joins Ultima Genomics in offering a duplex sequencing workflow for use in sequencing applications requiring high accuracy. Ultima’s PPM-seq also keeps both strands so that they’re sequenced together.
Duplex sequencing has recently been in the headlines as Guardant Health has faced hundreds of millions of dollars in legal penalties for infringement of patents held by TwinStrand Biosciences, a University of Washington spinout.
Whether Illumina is expecting a legal fight isn’t clear. “Illumina has developed its own proprietary technology,” a company spokesperson told Ion Genomics. “We do license third-party patents where appropriate; however, we cannot comment on those confidential agreements.”
Whether Illumina will introduce duplex sequencing into other applications also isn’t clear. Some of Illumina’s other oncology products have latent capability to incorporate with duplex sequencing, one expert on the subject told Ion Genomics on the sidelines of AMP.
The kit launch also comes as pharmaceutical companies are turning to MRD as a primary endpoint in clinical trials for cancer drugs. The launch once again pits Illumina against some of its customers offering MRD testing for pharma clients — a meaningful and fast-growing business.
For example, Adaptive Biotechnologies reported Nov. 9 that in the third quarter, pharma MRD revenue from testing (i.e., excluding milestones) was up 55 percent year over year, compared to 41 percent growth in clinical testing. Adaptive also noted that it had a testing backlog worth more than $270 million, an increase of 34 percent from the prior-year period.
Kits for Illumina’s early access program are expected to ship in the first quarter of 2027.
More Illumina News
Illumina will lay off 51 workers at its San Diego headquarters come January, according to a filing with the California Employment Development Department.
“We are making targeted changes across select areas of our business to better align resources with our priorities and the needs of our customers,” an Illumina spokesperson said in an email. However, the company did not respond to questions about whether there were additional layoffs and which departments will see cuts.
Other Genomics News
10x Genomics Inks Single-Cell Autoimmune Research Collabs in Germany, South Korea
10x Genomics announced Nov. 16 two new research collaborations to identify blood-based biomarkers of disease activity and treatment response in autoimmune disease, using the company’s single-cell sequencing technology.
10x is also hiring for a key position at the intersection of genomics and AI. The associate director of AI market development should be able to “explain to pharma discovery leaders why large-scale screens are the input that makes those [AI] models useful, and they know how to turn that conversation into adoption of 10x platforms.” The published salary range is $206,900 to $279,900
Ansa Biotechnologies Raises $71.5M Series C Round for Enzymatic DNA Synthesis
Ansa Biotechnologies on Nov. 18 announced the close of a $71.5 million Series C financing, bringing its total funding to $211 million.
Twist Bio Holds AI-Driven 2027 Outlook at $100M Despite 175 Percent Growth in FY26
Twist Biosciences’ artificial intelligence (AI)-based drug discovery revenue nearly tripled in fiscal year 2026, however, the company did not raise its $100 million target for that segment in fiscal year 2027.
Google DeepMind introduced AlphaGenome 2, an updated artificial intelligence model that predicts the effects of changes in DNA sequence, on Nov. 11.
Now, the predictions come in the context of cell type and even cell state. “Importantly, it allows researchers to predict variant effects in disease-relevant cells that would be missed in broad-tissue models, as well as predictions for cell and disease states that the model hasn’t seen before,” the team behind AlphaGenome 2 wrote in a blog post.
As reported by Nature News, AlphaGenome 2 was trained on “single-cell gene activity and other measurements made in more than 100 million cells, across 68 tissues.”
“What makes AlphaGenome 2 exciting is how it adapts directly to new single-cell data without retraining, predicting how DNA variants act in newly profiled cell states from even a small sample of cells,” single-cell expert Sarah Teichmann of the Human Cell Atlas and University of Cambridge, said in a statement.
The announcement follows the Sept. 8 launch of AlphaGenome Atlas, a data product that contains precomputed predictions for the molecular effects of roughly 9 billion single-nucleotide variants, or every possible single-letter change in the human genome.
On Nov. 16, Guardant Health completed a private offering of $550 million in senior notes due 2032.
Yassmine Akkari of Nationwide Children’s Hospital has taken over as AMP president. I’ve spoken to her many times over the years about NGS-based testing and got a chance to hear how she’ll approach the job on the floor of the AMP meeting in Seattle last week.
‘Live’ with AMP President Yassmine Akkari
SEATTLE - Pediatric testing was one of the themes of the annual meeting of the Association for Molecular Pathology (AMP) and could be a focus over the next year under new President Yassmine Akkari, whose home institution is Nationwide Children’s Hospital in Cincinnati.
GeneDx announced Nov. 18 that Everett Cunningham will succeed Katherine Stueland as CEO and join the Board, effective on or before December 15, 2026. Cunningham was previously CEO at Quanterix, which announced his departure earlier in the day. Before that, he was chief commercial officer at Illumina. According to Canaccord Genuity Analyst Kyle Mikson, “Stueland will remain with [GeneDx] in an advisory capacity through Jan. 31, 2027, to support a smooth transition.”
Mayo Clinic has selected Matthew Callstrom as CEO, starting Jan. 1, 2027, suggesting that AI is a big part of its future. Callstrom, a diagnostic radiologist, is medical director for Mayo Clinic Strategy and its AI Program. “He has helped shape Mayo Clinic’s organizational strategy and advance the responsible integration of AI into medicine,” Mayo said in a statement.
MyDNA and its laboratory operating company, Gene By Gene, have opened a new genomic laboratory in Glasgow, Scotland at the Queen Elizabeth University Hospital. The lab joins facilities in Houston and Melbourne, Australia.
My Omics Reading List
Huang, Hu, Na, et al. “Partially functional hypomorphic missense variants in BRCA2 are reduced penetrance pathogenic variants.” Nature Communications. Nov. 17, 2026.
Researchers from Mayo Clinic and Ambry Genetics studied 70 so-called “hypomorphic” BRCA2 gene variants, which only partially disrupt BRCA2 function.
“The 34 ‘strong’ hypomorphs with greatest effects on function are associated with moderate risks of female breast cancer and later ages of diagnosis than pathogenic variants,” the authors wrote. People who inherit these specific variants are estimated to have a 20 to 25 percent lifetime risk of developing breast cancer, compared to a lifetime risk of more than 50 percent for more pathogenic variants.
“This shows that not all harmful BRCA2 variants carry the same level of breast cancer risk,” Mayo researcher Fergus Couch, the study’s senior author, said in a statement. “Understanding these differences could help us better match cancer prevention and screening strategies to an individual’s actual risk.”
Elsewhere on The Internet
This will probably be fine, could even be good, but I guess Robert Pattinson is just taking all the jobs now?
Anyone applying to that 10x AIxBio position mentioned earlier better hope he doesn’t want that role, too…





